Please use this identifier to cite or link to this item:
|Title:||Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now||Authors:||Freire-Moran, Laura
So, Anthony D.
Monnet, Dominique L.
|Issue Date:||2011||Publisher:||CHURCHILL LIVINGSTONE||Source:||DRUG RESISTANCE UPDATES, 14(2). p. 118-124||Abstract:||Two commercial databases (Pharmaprojects and Adis Insight R&D) were queried for antibacterial agents in clinical development. Particular attention was given to antibacterial agents for systemic administration. For each agent, reviewers were requested to indicate whether its spectrum of activity covered a set of selected multidrug-resistant bacteria, and whether it had a new mechanism of action or a new target. In addition, PubMed was searched for antibacterial agents in development that appeared in review articles. Out of 90 agents that were considered to fulfil the inclusion criteria for the analysis, 66 were new active substances. Fifteen of these could be systemically administered and were assessed as acting via a new or possibly new mechanism of action or on a new or possibly new target. Out of these, 12 agents were assessed as having documented in vitro activity against antibiotic-resistant Gram-positive bacteria and only four had documented in vitro activity against antibiotic-resistant Gram-negative bacteria. Of these four, two acted on new or possibly new targets and, crucially, none acted via new mechanisms of action. There is an urgent need to address the lack of effective treatments to meet the increasing public health burden caused by multidrug-resistant bacteria, in particular against Gram-negative bacteria. (C) 2011 Elsevier Ltd. All rights reserved.||Notes:||[Cars, Otto] Uppsala Univ, Dept Med Sci, SE-75105 Uppsala, Sweden. [Freire-Moran, Laura; Aronsson, Bo] EMA, London, England. [Manz, Chris; So, Anthony D.] Duke Univ, Strateg Policy Unit Act Antibiot Resistance ReAct, Durham, NC 27706 USA. [Gyssens, Inge C.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands. [Gyssens, Inge C.] CWZ Hosp, Nijmegen, Netherlands. [Gyssens, Inge C.] Hasselt Univ, Diepenbeek, Belgium. [Monnet, Dominique L.] European Ctr Dis Prevent & Control ECDC, Stockholm, Sweden. [Cars, Otto] Univ Uppsala Hosp, Dept Infect Dis, S-75185 Uppsala, Sweden.||Keywords:||Antibiotics; Antimicrobial resistance; Antibiotic resistance; Antibacterial drug development; Novel antimicrobials; Multidrug resistant bacteria; Gap-analysis; EMA; ECDC; ReAct||Document URI:||http://hdl.handle.net/1942/12017||ISSN:||1368-7646||e-ISSN:||1532-2084||DOI:||10.1016/j.drup.2011.02.003||ISI #:||000291375900008||Category:||A1||Type:||Journal Contribution||Validations:||ecoom 2012|
|Appears in Collections:||Research publications|
Show full item record
checked on Sep 3, 2020
WEB OF SCIENCETM
checked on May 21, 2022
checked on May 20, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.